Latigo reports Q2 2026 results, NEJM publication for onzotrigine, and completed IPO

Latigo Biotherapeutics reported second quarter 2026 financial results on September 3, 2026, alongside pipeline and corporate updates.

The company said The New England Journal of Medicine published positive clinical trial results for onzotrigine in moderate-to-severe pain following abdominoplasty, with the study meeting its primary endpoint of the Summed Pain Intensity Difference over 48 hours versus placebo with high statistical significance and demonstrating rapid, clinically meaningful pain relief, favorable tolerability, and opioid-sparing potential, according to the company.¹ Latigo said this marks only the second original research publication in NEJM reporting clinical results for a novel drug for acute pain in the last 15 years.¹

On next steps, Latigo said it plans to initiate a randomized, double-blind, placebo-controlled Phase 3 clinical trial in patients with moderate-to-severe acute pain after bunionectomy surgery as well as a single-arm, open-label Phase 3 safety trial in the second half of 2026.¹ The company said it expects to report topline results from the Phase 3 bunionectomy and open-label safety clinical trials in the second half of 2027.¹ Separately, Latigo said it completed bioavailability studies for the onzotrigine intravenous (IV) formulation with preliminary data indicating approximately 100% oral bioavailability.¹

For LTG-321, targeting chronic pain, the company said it initiated a randomized, double-blind, placebo-controlled, within-patient crossover Phase 2 clinical trial in approximately 120 patients with osteoarthritis of the knee, being conducted at multiple sites in Denmark with enrollment underway.¹ Topline results are expected in the second half of 2027.¹

On corporate matters, Latigo said it completed an upsized initial public offering in August 2026, including the full exercise by the underwriters of their option to purchase additional shares, raising gross proceeds of $397.4 million, before deducting underwriting discounts and commissions and other offering expenses.¹

The company reported cash and cash equivalents of $55.0 million as of June 30, 2026, which together with IPO net proceeds it said are projected to fund current operating plans into 2029.¹